Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 G284R |
| Therapy | Lapatinib + Trastuzumab |
| Indication/Tumor Type | breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 G284R | breast cancer | predicted - sensitive | Lapatinib + Trastuzumab | Case Reports/Case Series | Actionable | In a clinical case study, the combination treatment of Herceptin (trastuzumab) and Tykerb (lapatinib) in a patient with breast cancer harboring ERBB3 (HER3) G284R resulted in antitumor efficacy, demonstrating a complete metabolic response after day 14 of treatment, a partial response after 8 weeks of treatment, and no clinical evidence of disease after 40 weeks of treatment (PMID: 25953157). | 25953157 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25953157) | Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. | Full reference... |